Ibritumomab Tiuxetan

What Ibritumomab Tiuxetan Means in Everyday Medical Language

Ibritumomab tiuxetan is a medicine designed to treat certain types of B-cell non-Hodgkin lymphoma, a cancer that affects a type of white blood cell called B cells. It is made by combining a lab-made antibody called ibritumomab with a compound called tiuxetan, which allows a small amount of radioactive material to be attached. The antibody specifically finds and sticks to a protein called CD20 on the surface of B cells, including lymphoma cells. The attached radioactive substance, usually yttrium-90, delivers radiation directly to these cancer cells to help kill them. This targeted approach aims to attack cancer cells while reducing harm to healthy tissues.

Why Ibritumomab Tiuxetan Can Matter in Cancer Care

This treatment is important because it offers a way to treat certain B-cell lymphomas that have come back after other treatments or have not responded well. It is often used together with another antibody therapy called rituximab, which also targets CD20 but works differently. By combining these therapies, doctors hope to improve the chances of controlling the lymphoma. Ibritumomab tiuxetan was the first radioimmunotherapy drug approved by the FDA for cancer treatment and remains an option for adults with specific lymphoma types.

What Patients Might See, Feel, or Be Told When This Term Comes Up

If your care team discusses ibritumomab tiuxetan, you might hear it called Zevalin or see related names like 90Y-Zevalin or IDEC-Y2B8. These all refer to the same treatment. The therapy usually starts with an infusion of rituximab, followed by the ibritumomab tiuxetan dose. Because it involves radiation, you may have questions about safety; the amount used is carefully controlled to target cancer cells while limiting exposure to healthy tissue. Side effects and treatment details should be discussed with your doctor to understand what to expect.

Related Forms and Uses: Imaging with 111In-Ibritumomab Tiuxetan

Where You Might See the Term and What It Does Not Automatically Mean

You may find ibritumomab tiuxetan mentioned in medical reports, treatment plans, or clinical trial information. Seeing the name does not always mean you are receiving the treatment; sometimes it refers to imaging or research. Also, a positive scan with the imaging form does not always mean cancer is present, as normal B cells can also take up the antibody. Always ask your care team to explain what the term means in your specific situation.

How Doctors Use Ibritumomab Tiuxetan in Care

Common Questions and Next Steps